Please login to the form below

Not currently logged in
Email:
Password:

UCB admits Keppra misbranding offence

UCB is to pay $34m after admitting to off-label marketing of its epilepsy drug Keppra as a treatment for migraine

UCB has agreed to pay $34.4m to settle a dispute with the US Department of Justice regarding off-label marketing of its epilepsy drug Keppra.

The Belgian company's US subsidiary pleaded guilty to a single misdemeanour violation and entered into a separate civil settlement agreement to resolve allegations relating to misbranding of Keppra (levetiracetam) as a migraine treatment.

Greg Duncan, UCB's president for North American operations, said: "We have worked diligently over the years to enhance our compliance programme and we continue to evolve our compliance efforts to meet the changing demands of the regulatory environment in which we operate. We are pleased to have resolved this matter."

The events occurred more than six years ago, and UCB said it cooperated fully with the US authorities since learning of the investigation in 2008. It also signed a five-year corporate integrity agreement with the US Department of Health and Human Services.

13th June 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...